Mavacamtem, an oral cardiac myosin inhibitor that reduces actin-myosin cross-bridge formation, has been shown to relieve symptoms, reduce left ventricular outflow tract (LVOT) obstruction, and increase exercise tolerance in patients with hypertrophic cardiomyopathy (1, 2).